Skip to main content


Generating validated targets and preclinical drugs with a curative potential for targeted treatments of cancer.

At NeoTargets, we utilize our proprietary oncotarget discovery platform to identify drug targets that demonstrate significant potency and safety against primary cancer cells while minimizing effects on vital tissues and normal cells. Our pipeline focuses on early-stage drug development projects catering to hematological malignancies and glioblastoma.


The survival rate for a broad range of cancers remains unacceptably low. In addition, 97% of clinical studies against cancer fail, mainly because of high toxicity and low efficacy of the drug candidate. A major reason behind this low success rate in clinical studies can in most cases be traced back to poor assessment during preclinical research. There is a lack of systematic assessment of drug targets, and routinely model systems with low predictive value that are insufficient to assess the efficacy of targets and drugs are engaged.

At NeoTargets we can increase the probability that candidates selected will not fail in clinical studies, by selecting the best targets against the disease and followingly validate them before the clinical studies are initiated, thereby saving precious time, money and ultimately also lives.

The team behind NeoTargets has long-standing expertise in cancer biology, drug target discovery and drug discovery with a proven ability to bring successful projects to the clinics. We have established a pioneering oncotarget discovery platform, consisting of an in-silico target assessment tool for systematic identification and prioritisation of targets with optimal characteristics (e.g. “druggability” and selectivity against cancer cells).

Selected candidate targets are functionally validated in a stepwise fashion on:

  1. Relevant cancer cells
  2. Translational cell models for toxicity
  3. Well-characterised patient samples, including cancer-initiating cell populations
  4. Patient-derived xenograft (PDX) mouse models

Validated targets are further investigated for mechanisms of action and potential molecular biomarkers.

Our efforts are directed towards the generation of validated targets and preclinical drugs demonstrating proven efficacy against primary cancer cells, including cancer-initiating cells, while minimizing impacts on vital tissues. By doing so, we strive to offer targets and preclinical drugs with the potential for curative interventions, facilitating the development of novel targeted treatments.

Mission, vision and strategy


Our mission is to identify optimal therapeutic targets and to develop safe and efficient drugs with a curative potential for the treatment of cancer.


Our vision is to become a leading developer of targeted and effective therapeutic approaches for patients with unmet medical needs.


We identify and validate optimal therapeutic targets using our pioneering oncotargetTM discovery platform. These targets are the basis for preclinical drug development projects that are conducted by NeoTargets and its partners.

Commercialisation of the products are pursued trough collaborations with established drug companies based on either sale and licensing of the validated drug targets or preclinical drugs.

Research and Technology


At NeoTargets, our unique oncotarget discovery platform comprises a proprietary bioinformatic tool used for the identification of optimal target candidates, followed by their functional validation in translational model systems, encompassing toxicity models, patient samples, and animal models.


The in-silico target assessment tool

Approximately 15% of clinical trials are discontinued due to target toxicity arising from harmful targets. At NeoTargets, we have developed a unique in silico assessment tool, enabling the identification of cancer-specific and safe targets with optimal characteristics across 135 different cancer types. Through a comprehensive comparison of our target data with clinical information, we can effectively eliminate all harmful targets, surpassing the performance of other available tools tested thus far (e.g., DepMap).


Validation of cancer dependencies

Firstly, identified candidate targets undergo validation for their significance in various relevant cancer cell lines specific to the indication of interest. Typically, over 90% of the candidates successfully pass this crucial validation step.


Functional assessment of toxicity in normal healthy cells

Toxicity in vital organs, including the cardiovascular, liver, hematologic, and nervous systems, poses a significant challenge in cancer treatment. Therefore, to mitigate the risk of toxicity during downstream drug testing, all identified targets undergo thorough investigation for potential harmful effects on normal blood cells, cardiomyocytes, hepatocytes, and neurons at the earliest stages of the process.


Validation of targets using primary cancer cells

The targets will undergo validation to assess their significance in well-characterized patient samples, facilitating the identification of targets suitable for combating specific subtypes of cancer (e.g., P53 mutated cancer). Given the curative potential of strategies targeting cancer-driving cells, our priority lies in the identification of targets that can effectively eliminate this particular cell type.


Validation of candidate targets in xenograft animal models

To ascertain whether the inhibition of the targets can impede disease progression and enhance survival rates, we will validate them using patient-derived xenograft (PDX) mouse models.


The molecular mechanisms behind the selective importance in cancer cells

The ultimate target candidates will undergo investigation for their mechanisms of action and predictive markers, utilizing functional genomics.


Projects and therapeutic areas

Collaboration projects

Acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive haematological disorder with dismal prognosis. The standard treatment for AML is chemotherapy but this regimen causes severe side effects and have low curative potential. In collaboration with the Swedish drug development company Sprint Bioscience, we are validating optimal therapeutic targets for AML using our technology platform.

Pipeline of projects available for partnerships

Multiple myeloma

With an aim to address the challenges posed by multiple myeloma, we have identified 25 promising target candidates for intensive validation. Notably, these candidates exhibit essentiality in multiple myeloma cells while sparing normal cells. Our ongoing research incorporates an intricate selection process, considering factors such as overall survival impact, crystal structure availability, and existing investigational compounds.

Pancreatic cancer

Pancreatic cancer boasts the highest mortality rate among all cancers, with a mere 12% survival rate over five years. In response to this formidable challenge, we have developed patient-derived in vitro and in vivo model systems and identified more than 20 optimal candidate targets.

Glioblastoma multiforme

The devastating impact of glioblastoma multiforme demands urgent attention. In our research on this lethal brain cancer, we have identified 25 promising candidates slated for rigorous validation using patient-derived cancer cells and advanced animal models.

Ovarian cancer

Ovarian cancer stands as the leading cause of mortality among women with gynecological cancers. In 2022, over 313,000 new cases and 207,000 deaths were reported. In our efforts, we have identified a set of highly promising target candidates, and we’ve established clinically relevant model systems for further exploration.

Liver cancer

Liver cancer ranks among the most prevalent cancers and stands as the third leading cause of cancer-related deaths. Annually, over 900,000 patients worldwide receive a diagnosis. Given the high unmet therapeutic need associated with liver cancer, we have identified a set of highly promising candidates that will undergo testing in patient material.

Secondary bone cancer

Secondary bone cancer is an advanced and challenging form of cancer, often associated with a poor prognosis and considered incurable. In response to this pressing medical need, we have identified 30 promising candidate targets. These targets will undergo rigorous functional and pharmacological validation in state-of-the-art model systems specifically designed for this disease.


Lymphomas encompass a diverse group of diseases, each with specific subtypes and varying medical needs. We have identified the most promising candidate targets for these subtypes, and we will validate them using well-characterized patient samples.

Nondisclosed projects

Other cancer types than the above with unmet medical needs with existing translational model systems.

NeoTargets continues to broaden its portfolio, addressing various cancer types with unmet medical needs. Our dedication to leveraging established translational model systems underscores our commitment to advancing novel treatment solutions for a range of cancers.

Collaborations and partnerships

To secure a professional management and further successful development of the company, NeoTargets has partnered with the Danish company, Marigold Innovation. By merging the senior biotech executive team from Marigold with the scientific group from NeoTargets, we have established a dynamic group with complementary competences and strong execution power.
Research collaborations and partnerships are essential in successful R&D, and a central part of NeoTargets’ strategy to maximise quality, progress, and commercial goals for our projects. In addition to our expertise, well-established model systems, and unique technology, NeoTargets collaborates closely with various researchers, partners, and clinicians for complementing biological and clinical expertise as well as state-of-the-art model systems with high translational value.
NeoTargets has an ongoing research collaboration project in acute myeloid leukemia with the Swedish listed drug development company, Sprint Bioscience.

Business model

NeoTargets’ business model: Focus on asset creation and out-licensing/partnering
NeoTargets has established a full platform for the development of safe, new cancer therapeutics from target identification to preclinical drug candidate validation.
Initially, the proprietary oncotarget platform is applied to generate comprehensive databases of potential drug targets with pre-validated efficacy and safety in different types of cancer.
Subsequently, drug development projects for selected targets are initiated, now using the platform to screen a diverse range of drug candidates from libraries of traditional small molecule inhibitors, molecular glue degraders, and bifunctional protein degrading molecules such as PROTACs.
For each specific target:candidate combination, the projects aim to generate preclinical proof-of-concept, thereby generating a portfolio of assets that can be partnered, out-licensed, or sold at various stages of development.
This approach allows the Company to explore different mechanisms of action and therapeutic strategies to combat cancer and provide optimal opportunities to partners or licensees to advance the drug candidates further and bring them to market.


Julian Walfridsson

Founder, CSO and board director

Associate Professor Group Leader Karolinska Institutet Email: Expert in hematological malignancies, glioblastoma, cancer biology, bioinformatics, molecular biology,  functional genomics and cell biology.

Peter Horn Møller

Co-founder and board director

Partner & founder, Marigold Innovation Email: Researcher, patent attorney, executive manager, strategic business developer and start-up energizer bridging science, business, IP, academia and industry. CEO & co-founder at Zyneyro

Charlotte Dyring

Co-founder and CEO

CEO & Partner, Marigold Innovation Email: Co-founder and former CEO of ExpreS2ion Biotechnologies, listed on Nasdaq First North Stockholm (EXPRS2). Board Director at Saromics AB

Mikael Altun

Co-founder and board director

Associate Professor and Group Leader Karolinska Institutet Email: Expert in chemical, proteasome and molecular biology, biochemistry, assay development, PROTACs, and small molecules development.

Please contact us for any questions

    NeoTargets AB

    Vegagatan 11B
    17234 Sundbyberg
    Sweden 559353-1527
    Phone: +46 709 526 897